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Abstract 
 
The prevention of recurrent events after ischaemic stroke and transient ischaemic 
attack (TIA) is well established and based on life style changes, antithrombotics, 
statins, antihypertensives and carotid surgery. The international IRIS trial assessed 
whether pioglitazone, a glucose-lowering insulin-sensitising drug, would reduce 
recurrent vascular events in patients with ischaemic stroke or TIA. After 4.8 years, 
pioglitazone therapy was associated with reduced vascular events and new diabetes, 
and an increase in weight, oedema and bone fractures. Pioglitazone may add to the 
strategies for preventing further events in patients with stroke or TIA. 
 
 
Commentary 
 
The prevention of recurrent events after ischaemic stroke and transient ischaemic 
attack (TIA) is well established and based on life style changes (exercise, diet, weight 
reduction, alcohol moderation, smoking cessation), antithrombotics, statins, 
antihypertensives and carotid surgery. Th se interventions, when prescribed and 
delivered, can together reduce recurrence by up to 80%. Hence, finding an additional 
intervention that would further reduce recurrent events in a reasonable proportion of 
patients has been considered challenging for many years. Thus, the positive findings 
of the IRIS secondary prevention trial,(1) which aimed to moderate insulin resistance 
in non-diabetic patients, adds hope that we can further reduce recurrent events on 
top of established interventions. IRIS studied pioglitazone, a member of the 
thiazolidinedione class of peroxisome proliferator-activated receptor gamma (PPAR-γ, 
or glitazone receptor) agonists that has an insulin sensitising role. Although licensed 
for lowering glucose in diabetic patients, pioglitazone has not previously been tested 
in non-diabetic stroke patients in a large trial. 
 
IRIS was an international double-blind trial in patients with recent ischaemic stroke or 
TIA.(1) Patients did not have diabetes but had insulin resistance determined as an 
elevated ‘homeostasis model assessment of insulin resistance’ index (HOMA-IR >3 
(2)). Key exclusion criteria included a history of heart failure or bladder cancer, and 
severely disabling stroke. Almost two-thirds of patients screened for the trial were 
deemed to be resistant to insulin.(1) The majority of patients were taking 
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conventional secondary prophylaxis at baseline. 3876 patients were randomised to 
pioglitazone (target dose 45 mg daily) or placebo for an average of 4.8 years (15,903 
person years). At final follow-up, fatal or nonfatal stroke or myocardial infarction 
(primary outcome) was 9.0% in the pioglitazone group and 11.8% in the placebo 
group, amounting to a hazard ratio of 0.76 (95% confidence intervals 0.62-0.93, 
p=0.007), absolute risk reduction 2.8%, and relative risk reduction 23.7%.(1) None 
of the pre-specified subgroups showed an interaction between treatment and primary 
outcome. The development of diabetes was less in the pioglitazone group (3.8% vs 
7.7% participants, p<0.001). The rate of death from any cause did not differ between 
the treatment groups. However, pioglitazone was associated with weight gain (mean 
gain at 4 years: 2.6 kg vs. -0.5 kg, p<0.001) and oedema (35.6% vs 24.9% 
participants, p<0.001) and, importantly, more bone fractures needing surgery or 
hospitalisation (5.1% vs 3.2% participants, P=0.003).(1) Earlier concerns that 
pioglitazone might increase bladder cancer (3) and heart failure (4) were not seen in 
IRIS. Overall, treatment with pioglitazone in 100 patients with insulin resistance and 
recent ischaemic stroke/TIA for about 5 years might prevent three patients from 
having a stroke or MI, but contribute to the development of serious bone fractures in 
two patients.(1) The results are compatible with a published systematic review of 
earlier and smaller trials of PPAR-γ drugs (pioglitazone, rosiglitazone),(5) a trial of 
pioglitazone in patients with diabetes,(6) and a systematic review of the relationship 
between glitazones and fractures,(7) i.e. glitazones reduce vascular events but 
increase oedema, weight gain and fractures. 
 
The IRIS results are important generically in two ways: IRIS is the first demonstration 
that a glucose-lowering drug with insulin-sensitising properties reduces stroke and 
myocardial infarction in patients with recent ischaemic stroke or TIA; and assessment 
of insulin resistance may need to become a routine part of the investigational work-up 
of patients with a recent stroke or TIA. 
 
So do these results suggest we should start using pioglitazone in insulin resistant 
patients? First, if a manufacturer had sponsored and funded IRIS, a second 
randomised controlled trial might be required to confirm the results before a 
marketing authorisation was issued. IRIS was funded by the US government and 
pioglitazone is already licensed (and available in generic formulations) although its 
use in non-diabetic patients would be off-label. Although it is unlikely that the results 
of IRIS reflect chance (since they are comparable with the results of earlier trials and 
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systematic reviews) the need for a second trial has to be considered. Second, trials of 
other insulin-sensitising drugs such as metformin may be warranted in patients with 
ischaemic stroke or TIA, not least because this ‘old’ antidiabetic drug may have life-
extending properties. Third, patients prescribed pioglitazone would need to fulfil the 
specific and somewhat stringent IRIS inclusion and exclusion criteria, as listed 
above.(8) Fourth, the HOMA-IR test is not used frequently in clinical practice; in IRIS, 
HOMA was assayed centrally in core laboratories. HOMA can be calculated from local 
assays of fasting glucose and insulin although laboratories will need to standardise the 
latter. Alternatively, other surrogate markers of insulin resistance, such as the 
individual components of HOMA, waist circumference, or HbA1c, could be used 
although these would require validation in stroke patients. And last, the types and 
sites of fractures occurring in IRIS need to be identified so that patients at particular 
risk can be recognised in advance. For example, would DEXA scan measurement of 
bone mineral density identify patients at risk, or concurrent administration of calcium 
and vitamin D reduce fracture risk? In a meta-analysis of previous trials of glitazones, 
increased fracture risk was associated with female sex but not age or duration of 
exposure.(7) No doubt future IRIS publications will examine this issue in more detail. 
 
In summary, whilst the positive results from IRIS are very welcome, two uncertainties 
need further consideration and research prior to routine use, in particular relating to 
the need for widespread and standardised measurement of insulin resistance, and 
better understanding of the cause and risk factors for the development of fractures. In 
the meantime, patients who are likely to have insulin resistance can have the results 
of IRIS and potential benefits and risks of pioglitazone discussed with them, and they 
should be reminded that life-style changes also have insulin-sensitising effects. 
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